Muraglitazar is a dual (α/γ) PPAR activator. Dual receptor activation may improve glycaemic and lipid profiles in patients with type 2 diabetes mellitus. This randomised double-blind trial in 1,477 drug-naive patients with type 2 diabetes compared the efficacy and safety of muraglitazar (0.5, 1.5, 5, 10, and 20 mg) with pioglitazone (15 mg). Endpoints included changes in HbA 1C and plasma lipids, last observation carried forward over 24 weeks. At week 24, mean changes from baseline in HbA 1C ranged from -0.25% to -1.76% with muraglitazar (p≤0.0008, 0.5 mg versus each higher muraglitazar dose), compared with -0.57% with pioglitazone. At week 12, tri-glycerides decreased 4-41% with muraglitazar and 9% with pioglitazone. High-density lipoprotein cholesterol increased 6-23% with muraglitazar and 10% with pioglitazone. Oedemarelated events occurred with muraglitazar in a dose-dependent incidence (range 9-40%), and at 14% with pioglitazone. Overall, muraglitazar produced simultaneous dose-dependent improvements in glycaemic and lipid parameters in drugnaive patients with type 2 diabetes mellitus.
Introduction
Type 2 diabetes is a complex disease characterised by multiple metabolic disorders, including insulin resistance and lipid abnormalities. For patients with type 2 diabetes, maintaining tight glycaemic control and regulation of lipid concentrations are important therapeutic goals for effective disease management 1,2 because decreasing HbA 1C and triglyceride levels and increasing HDL-c levels can help reduce the risk for cardiovascular disease. 2, 3 The integral role of PPAR-γ in maintaining glucose homeostasis and PPAR-α in regulating lipid metabolism has led to the availability of synthetic selective PPARγ agonists (e.g. thiazolidinediones) that improve insulin sensitivity and glycaemic control and selective PPAR-α agonists (e.g. fibrates) that improve plasma lipid profiles. 4 Thus, therapy capable of activating both α and γ PPAR receptors may simultaneously improve glycaemic control and lipid abnormalities typically seen in patients with type 2 diabetes. 5 Muraglitazar is a novel, dual (α/γ) PPAR activator that belongs to the class of potential antidiabetic agents called glitazars. Two 24-week clinical studies that compared muraglitazar with diet and exercise 6 or pioglitazone 7 have demonstrated improvement in HbA 1C and lipid parameters with muraglitazar therapy. A 52-week study comparing muraglitazar with glimepiride also demonstrated glycaemic improvements with muraglitazar. 8 Development of the drug was discontinued after results from a large phase 3 programme raised the possibility that it was associated with an increased risk for cardiovascular events. This article presents the results of a phase 2 study evaluating the efficacy and safety of a broad range of doses of muraglitazar (0. 5, 1.5, 5, 10, and 20 mg) and pioglitazone 15 mg in drugnaive patients with type 2 diabetes.
Methods
After completing a 2-week dietary and placebo lead-in phase, eligible patients were randomised in this six-arm, parallelgroup, double-blind, dose-ranging, dose-comparison controlled trial to 24 weeks of once-daily treatment with one of five muraglitazar doses (0. 5, 1.5, 5, 10, or 20 mg) or pioglitazone 15 mg. Muraglitazar 0.5 mg was selected to establish a noeffect or a minimal-effect dose for the range of muraglitazar doses evaluated. Since patients entering this trial were drugnaive, pioglitazone 15 mg, the minimum recommended dose for initiating pioglitazone therapy, was used as the therapeutic benchmark, although up-titration to the maximum recommended 45 mg dose was permitted as a 'rescue' dose to achieve adequate glycaemic control. Adequate glycaemic control was mandated in the study design; any patient who did not meet stringent, progressive criteria for adequate glycaemic control during treatment underwent a single upward dose titration as rescue therapy to a higher muraglitazar or pioglitazone dose, depending on assignment during randomisation. Pursuant to study design, the LOCF prior to up-titration of either muraglitazar or pioglitazone was used in the efficacy analysis to compare the dose groups. Mean daily glucose was calculated from four home blood glucose measurements taken 3 to 5 days before a study visit; patients with MDG concentrations > 240 mg/dL (> 13.3 mmol/L) at week 6, > 220 mg/dL (> 12.2 mmol/L) at week 8, > 200 mg/ dL (> 11.1 mmol/L) at week 12, and > 180 (> 10 mmol/L) at weeks 16 and 20 were advanced in dose to receive rescue therapy. Dose titrations were as follows: muraglitazar 0.5 mg and 1.5 mg were titrated to 5 mg, muraglitazar 5 mg to 10 mg, muraglitazar 10 mg to 20 mg, and pioglitazone 15 mg to 45 mg. Patients were discontinued if MDG targets were not achieved after the implementation of the singledose titration or if they already were receiving the maximum dose of study drug (muraglitazar 20 mg, pioglitazone 45 mg). Patients completing the 24-week treatment phase were eligible for participation in a long-term (≥ 2 year) treatment extension phase (data not presented).
The primary efficacy end point of this study was change from baseline in HbA 1C after 24 weeks of treatment. Secondary efficacy end points assessed at week 24 included change in FPG, insulin, and C-peptide plasma levels. At weeks 12 and 24, the percentage change from baseline for plasma triglyceride, HDL-c, non-HDL-c, Apo-B, LDL-c, total cholesterol, and free fatty acid concentrations were assessed. Safety and tolerability of study treatment over the 24-week treatment period was assessed by patient-reported or investigatorelicited AEs and clinical laboratory test results. Oedema-related events were sought proactively by clinicians who questioned and examined patients for the presence/status of bilateral pitting oedema of the ankles or feet.
Patients
Patients were screened for participation at 176 sites in the Unites States and Puerto Rico, 83 sites in nine European countries, and 34 sites in five other countries in the rest of the world. Patients eligible for participation included men and women aged 18 to 70 years with type 2 diabetes who were drug-naive -defined as patients who received medical treatment for diabetes (i.e. insulin and/or oral hypoglycaemic therapy) for less than 1 month. Patients had HbA 1C levels > 7.0% and ≤ 10.0%, BMI ≤ 41 kg/m 2 , and mean serum triglyceride concentration ≤ 600 mg/dL (≤ 6.78 mmol/L). Women of childbearing potential were required to use effective methods of contraception. During the first 12 weeks of the study, initiation of new lipid-lowering treatment was not permitted. Continuation of pre-study non-fibrate lipid-lowering therapy was permitted provided that doses remained stable during the initial 12-week period. After week 12, initiation or adjustment of non-fibrate lipidlowering treatment was permitted.
Patients were excluded from the study if they had symptomatic type 2 diabetes (i.e. marked polyuria and polydipsia with > 10% weight loss during the previous 3 months); history of diabetic ketoacidosis, hyperosmolar non-ketotic coma, or insulin therapy (except during hospitalisation or gestation) within the previous year; clinically significant anaemia or hepatic, renal, or cardiac disease (including New York Heart Association stage II, III, or IV CHF and/or left ventricular ejection fraction ≤ 40%); or contraindications or known sensitivity to PPAR agonists; or if they were pregnant or breastfeeding (women). Patients treated with fibrates and those initiated on or having had dosage adjustment of non-fibrate lipid-lowering therapy within the previous 4 weeks were also excluded.
This study was conducted in accordance with federal Good Clinical Practice guidelines and the principles of the Declaration of Helsinki; the protocol was approved by each study centre's institutional review board/independent review committee. All patients gave written informed consent before enrolment.
Statistical analyses
Efficacy analyses included all randomised patients who received at least one dose of study medication and had a baseline and at least one post-baseline assessment. HbA 1C analysis included patients who received at least 6 weeks of treatment; for dose-titrated patients, LOCF prior to dose titration was used. Fasting insulin and FPG analyses included only patients who received 8 days or more of treatment.
The primary efficacy analysis was a comparison of the mean change from baseline at week 24 (LOCF) in HbA 1C for muraglitazar 1.5, 5, 10, and 20 mg and the lowest dose group (muraglitazar 0.5) conducted using ANCOVA, with the difference between the post-treatment and baseline values as the dependent variable with treatment group as an effect, and the baseline value as a covariate. A similar ANCOVA model was used for dose group comparisons for mean changes from baseline in FPG, insulin, and C-peptide levels. Log-transformed data for lipid parameters at week 12 (LOCF) were analysed using ANCOVA on the logarithms of the post-treatment-to-baseline ratios with terms for treatment and logarithm of baseline value as the covariate. We calculated p-values for the comparison between muraglitazar 1.5, 5, 10, and 20 mg versus muraglitazar 0.5 mg for HbA 1C , FPG, insulin, and C-peptide. For all the remaining efficacy end points, only point estimates and 95% confidence intervals were computed.
Power calculations assumed a monotone dose response (efficacy maintained or increased with each dose increase) and used a two-sided Koch-Gansky sequential testing procedure with four experimental groups (muraglitazar 1.5, 5, 10, and 20 mg and one control group (muraglitazar 0.5 mg)). 9 The Koch-Gansky sequential testing procedure provided an overall significance level of 0.05; each comparison was performed at a two-sided level (α=0.05).
A sample size of 180 patients per group with post-baseline measurements (corresponding to 210 randomised per group assuming a 15% dropout rate) provided at least 85% power to detect a difference of 0.4% in mean change from baseline in HbA 1C between each dose level of muraglitazar (1.5, 5, 10 , and 20 mg) and muraglitazar 0.5 mg, assuming a standard deviation of 1%. The overall type 1 error was controlled at the 0.05 level.
Results

Patient disposition and demographics
A total of 1,479 patients were randomised to treatment with one of five muraglitazar doses or pioglitazone 15 mg. Of these patients, 1,477 received study drug (muraglitazar 0.5 mg (n=236), 1.5 mg (n=259), 5 mg (n=245), 10 mg (n=249), 20 mg (n=237)) or pioglitazone 15 mg (n=251); 1032 patients (70%) completed the 24-week treatment phase. To achieve and maintain pre-specified glycaemic control targets, 326 patients received a single upward dose titration: 93 (39%) for muraglitazar 0.5 mg, 82 (32%) for muraglitazar 1.5 mg, 48 (20%) for muraglitazar 5 mg, 24 (10%) for muraglitazar 10 mg, and 79 (31%) for pioglitazone 15 mg. A total of 445 patients discontinued the study because of lack of glycaemic control (n=210), AEs (n=88), withdrawal of consent (n=81), death (n=2), loss to follow-up (n=29), or non-compliance/protocol violation/other (n=35). Compliance was assessed by capsule count; good compliance was defined as > 80% and < 120% of count.
The treatment groups were well matched with respect to baseline demographics (total values: mean age, 54.1 y (±9.5); male/female ratio, 57%:43%; white, 82%; mean BMI, 31.1 kg/m 2 (±4.7)) and disease characteristics (mean HbA 1C , 8.24% (±1.09); mean FPG, 185.5 mg/dL (±54.2); mean duration of diabetes, 3.4 y (±4.2)).
Glycaemic efficacy
Effect on HbA 1C : In all treatment groups other than muraglitazar 0.5 mg, HbA 1C steadily decreased over the duration of the study (Figure 1a ). At week 24, dose-dependent reductions in HbA 1C levels from baseline ranging from -0.25% to -1.76% were observed in the groups treated with muraglitazar 0.5 to 20 mg and -0.57% for pioglitazone 15 mg (figure 1b). Compared with muraglitazar 0.5 mg (control dose), statistically significant greater mean HbA 1C reductions occurred with muraglitazar doses of 1.5 mg (p=0.0008) and 5, 10, and 20 mg (p<0.0001 for all comparisons).
Proportions of patients achieving HbA
1C goals: The proportions of patients achieving HbA 1C goals of ≤ 7.0% and ≤ 6.5% increased as the dose of muraglitazar increased. After 24 weeks of treatment, 62% to 85% of patients treated with muraglitazar doses greater than 1.5 mg achieved a final HbA 1C of ≤ 7.0%. The proportions of patients achieving HbA 1C ≤ 7.0% were 32% (0.5 mg), 44% (1.5 mg), 62% (5 mg), 76% (10 mg) and 85% (20 mg) compared with 47% of patients receiving pioglitazone. The proportions of patients achieving HbA 1C ≤ 6.5% were 18%, 29%, 43%, 59%, and 69%, respectively, compared with 26% for pioglitazone.
Effect on other glucose indices: At week 24, dose-dependent reductions from baseline in FPG, insulin, and C-peptide concentrations were observed in the muraglitazar groups (Table 1) . Compared with muraglitazar 0.5 mg, all muraglitazar doses of 1.5 mg and higher produced statistically significantly greater mean reductions in FPG concentration (p<0.0001 for all comparisons), and muraglitazar 5, 10, and 20 mg produced statistically significantly greater mean reductions in insulin levels (p<0.0001 for all comparisons) and C-peptide (p<0.0001 for all comparisons). Pioglitazone reduced FPG and insulin levels similar to those reported for muraglitazar 1.5 mg. Dose-dependent reductions in free fatty acid levels were observed with muraglitazar and pioglitazone at week 24 (table 1). The muraglitazar groups demonstrated similar, dose-dependent changes from baseline in free fatty acid levels at week 12: -8% (0.5 mg), -17% (1.5 mg), -27% (5 mg), -32% (10 mg), and -39% (20 mg). Pioglitazone 15 mg produced a -15% change in free fatty acid levels at week 12.
Effect on lipid concentrations: Dose-dependent reductions in triglycerides, non-HDL-c, and Apo-B plasma levels and dose-dependent increases in HDL-c plasma levels were observed with both agents at week 12 (table 1). Reductions in triglyceride concentrations were more pronounced in patients with baseline triglyceride concentrations > 150 mg/dL (≥ 1.7 mmol/L; n=760), in whom mean percentage changes were -12% (0.5 mg), -14% (1.5 mg), -32% (5 mg), -44% (10 mg), and -50% (20 mg) with muraglitazar and -21% with pioglitazone. At week 24, patients in the muraglitazar groups demonstrated changes in lipid parameters similar to those observed at week 12 (data not shown). Muraglitazar at all doses and pioglitazone 15 mg had a neutral effect on LDL-c or total cholesterol levels (table 1) .
Tolerability and safety profile: During the 24-week period, the incidence of AEs, treatment-related AEs, and discontinuations because of AEs was similar for muraglitazar 0.5, 1.5, and 5 mg, and pioglitazone 15 mg, and was higher for muraglitazar 10 and 20 mg (table 2). Serious AEs occurred in 2% (0.5 mg), 4% (1.5 mg), 5% (5 mg), 7% (10 mg), and 6% (20 mg) of patients treated with muraglitazar and in 3% of patients treated with pioglitazone 15 mg.
The most commonly reported AEs were oedema-related AEs and weight gain. Oedema-related AEs occurred in 11% (0.5 mg), 10% (1.5 mg), 9% (5 mg), 25% (10 mg), and 40% (20 mg) of patients treated with muraglitazar and in 14% of patients treated with pioglitazone 15 mg. Most of the muraglitazar-associated oedema-related AEs were mild (154/228; 68%) or moderate (60/228; 26%); severe cases occurred only for muraglitazar 10 mg (n=5, 2%) and 20 mg (n=9, 4%).
Oedema-related AEs resulted in discontinuation in one patient receiving muraglitazar 0.5 mg, 12 patients receiving 10 mg, and 22 patients receiving 20 mg. No patient receiving pioglitazone discontinued because of an oedemarelated AE. Mean changes in body weight were -1.1 kg (0.5 mg), -0.2 kg (1.5 mg), +1.6 kg (5 mg), +3.2 kg (10 mg), and +4.9 kg (20 mg) for muraglitazar and +0.2 kg for pioglitazone 15 mg.
Across all treatment groups, 13 patients experienced at least one cardiovascular event during the 24-week study. Of these patients, 11 received muraglitazar treatment (n=2 (1.5 mg); n=2 (5 mg); n=3 (10 mg), and n=4 (20 mg)), and two received pioglitazone at the time of onset of their first cardiovascular event (table 2). None of the patients receiving muraglitazar 0.5 mg experienced any cardiovascular events.
Seven cases of CHF were reported during the 24-week study; no cases with pioglitazone: five cases (mild (1), moderate (3), severe (1)) with muraglitazar 10 mg, and two cases (mild (1) severe (1)) with muraglitazar 20 mg. One case (muraglitazar 20 mg) was considered a serious AE. This case and the mild case in the 10 mg group were considered unlikely to be unrelated to study medication; the remainder were considered possibly or probably related to study medication. Three of the seven patients (two for muraglitazar 10 mg, one for 20 mg) discontinued the study per protocol. None of the CHF cases were fatal; all cases resolved either spontaneously (within 8 days), with use of diuretic therapy (within 3-8 days), or after withdrawal of study medication (within 16-26 days). Relevant baseline cardiac history in these cases included coronary artery disease and myocardial infarction (n=1), positive family history of coronary heart disease (n=1), Wolff-Parkinson-White syndrome (n=1), and a 3-year history of CHF (n=1). All cases had underlying hypertension and intermittent episodes of mild to moderate lower extremity oedema.
Confirmed hypoglycaemia events (defined as hypoglycaemic symptoms plus fingerstick glucose ≤ 50 mg/dL (≤ 2.8 mmol/L)) occurred in seven patients; all were treated with muraglitazar (n=2 each (5 and 10 mg), n=3 (20 mg)); none were considered serious or required treatment or dose adjustment. Six of the cases were mild and were associated with excessive physical activity or dietary indiscretion; one case (muraglitazar 10 mg) was severe, was not associated with any underlying contributory factors, and required no treatment.
There was no clinical evidence of liver, muscle, or renal toxicity. Two deaths occurred during the 24-week treatment phase: one following a motor vehicle accident (muraglitazar 10 mg) and one after a myocardial infarction (muraglitazar 
Discussion
This phase 2, dose-ranging trial was a unique study as a large number of patients were randomised (n=1,479), a wide range of muraglitazar doses (0.5-20 mg, representing a 40-fold range) were evaluated, and a high percentage of patients who avoided or tolerated treatment-related AEs were able to remain in the study with excellent glycaemic control over time and with titration to higher rescue doses of muraglitazar or pioglitazone 45 mg, as necessary. Over the course of 24 weeks, muraglitazar doses of 1.5, 5, 10, and 20 mg produced dose-dependent, clinically meaningful improvements in both glycaemic and lipid parameters. Each of these muraglitazar doses produced statistically significant mean reductions from baseline in HbA 1C (range, -0.57% to -1.76% (pioglitazone, -0.57%)) compared with the control dose (muraglitazar 0.5 mg), and the proportion of patients achieving HbA 1C goals of ≤ 7.0% and ≤ 6.5% with these doses was high (44%-85% (pioglitazone, 47%) and 29%-69% (pioglitazone, 26%), respectively). Significant dose-dependent reductions from baseline in insulin and C-peptide levels were observed for the muraglitazar 5 mg to 20 mg groups, suggesting that muraglitazar enhances insulin sensitivity in a dose-dependent fashion.
Similarly, treatment with muraglitazar 1.5 mg to 20 mg resulted in dose-dependent decreases in triglycerides (range, -6% to -41% (pioglitazone, -9%)) and Apo-B levels (range, -5% to -22% (pioglitazone, -5%)) and dose-dependent increases in HDL-c concentrations (range, 8% to 23% (pioglitazone, 10%)). Muraglitazar, at any dose, had a no effect on LDL-c concentrations.
Overall, muraglitazar 1.5 mg produced glycaemic and lipid effects similar to those of pioglitazone 15 mg. These two doses were associated with comparable decreases from baseline in HbA 1C (-0.57% for each) and in the percentage of patients achieving HbA 1C goals of ≤ 7.0% and ≤ 6.5%. Similar changes from baseline for muraglitazar 1.5 mg and pioglitazone 15 mg were reported in FPG (-20 mg/dL and -22 mg/dL, respectively), free fatty acid levels (-19% and -14%, respectively), triglycerides (-6% and -9%), HDL-c (+8% and +10%), and Apo-B (-5% for both).
Muraglitazar doses of 5 mg and lower were well tolerated throughout the 6-month study period. At these doses, the rates of treatment-related AEs and discontinuations because of AEs were similar to rates with pioglitazone 15 mg (approximately 20%). The PPARγ-mediated effects that resulted in dose-dependent improvement in glycaemic control resulted in dose-dependent occurrences of oedema-related AEs and weight gain. Weight gain is attributed to PPARγmediated stimulation of adipogenesis, redistribution of fat from visceral fat depots to subcutaneous fat depots, increased adipocyte fat storage capacity, 4, 10 and fluid retention as the result of sodium and water retention. 11 Thus, the trend toward increased weight gain and oedema-related AEs seen with greater glycaemic efficacy was not unexpected.
During our study, 13 patients experienced at least one cardiovascular event: 11 received muraglitazar and two received pioglitazone. Non-fatal CHF events occurred in seven patients receiving higher doses of muraglitazar (10 and 20 mg), many of whom had relevant underlying cardiac history. All cases of CHF resolved with diuretic therapy or discontinuation of study medication.
Conclusion
Muraglitazar over a dosage range of 0.5 mg to 20 mg demonstrated positive dose-dependent effects on glycaemic and lipid parameters in patients with type 2 diabetes. Dosedependent increases in weight gain and in the incidence of oedema were also observed. Comparison of the efficacy and safety data from all muraglitazar doses evaluated indicates that muraglitazar doses of 1.5 to 5 mg provided the best overall balance between efficacy (glycaemic and lipid) and safety.
